These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26499461)

  • 1. Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy.
    Pineda-Tenor D; Jiménez-Sousa MA; Rallón N; Berenguer J; Soriano V; Aldámiz-Echevarria T; García-Álvarez M; Diez C; Fernández-Rodríguez A; Benito JM; Resino S
    AIDS Res Hum Retroviruses; 2016 Mar; 32(3):226-31. PubMed ID: 26499461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients.
    Pineda-Tenor D; Berenguer J; Jiménez-Sousa MA; Guzmán-Fulgencio M; Aldámiz-Echevarria T; Carrero A; García-Álvarez M; Diez C; Tejerina F; Briz V; Resino S
    J Clin Virol; 2014 Nov; 61(3):423-9. PubMed ID: 25218243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.
    Jiménez-Sousa MA; Berenguer J; Rallón N; Pineda-Tenor D; Aldamiz-Echevarria T; Soriano V; García-Álvarez M; Vazquez-Morón S; Restrepo C; Carrero A; Benito JM; Resino S
    Liver Int; 2016 Sep; 36(9):1258-66. PubMed ID: 26836972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients.
    Jiménez-Sousa MA; Rallón N; Berenguer J; Pineda-Tenor D; López JC; Soriano V; Guzmán-Fulgencio M; Cosín J; Retana D; García-Álvarez M; Miralles P; Benito JM; Resino S
    J Clin Virol; 2015 Apr; 65():62-7. PubMed ID: 25766991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
    Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
    PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
    Guzmán-Fulgencio M; Berenguer J; Rallón N; Fernández-Rodríguez A; Miralles P; Soriano V; Jiménez-Sousa MA; Cosín J; Medrano J; García-Álvarez M; López JC; Benito JM; Resino S
    AIDS; 2013 May; 27(8):1231-8. PubMed ID: 23811951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy.
    Fernández-Rodríguez A; Berenguer J; Rallón N; Jiménez-Sousa MA; López JC; Soriano V; García-Álvarez M; Cosín J; Martínez P; Guzmán-Fulgencio M; Miralles P; Miguel Benito J; Resino S
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):113-9. PubMed ID: 25072612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
    Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
    Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.
    Medrano LM; Rallón N; Berenguer J; Jiménez-Sousa MA; Soriano V; Aldámiz-Echevarria T; Fernández-Rodríguez A; García M; Tejerina F; Martínez I; Benito JM; Resino S
    J Transl Med; 2016 Sep; 14(1):257. PubMed ID: 27590274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
    Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
    New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
    Mandorfer M; Neukam K; Reiberger T; Payer BA; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Meyer-Olson D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M
    AIDS; 2013 Nov; 27(17):2707-14. PubMed ID: 23835502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients.
    Guzmán-Fulgencio M; Berenguer J; Pineda-Tenor D; Jiménez-Sousa MA; García-Álvarez M; Aldámiz-Echevarria T; Carrero A; Diez C; Tejerina F; Vázquez S; Briz V; Resino S
    Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):385-93. PubMed ID: 25236396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
    Guzmán-Fulgencio M; Jiménez JL; Berenguer J; Fernández-Rodríguez A; López JC; Cosín J; Miralles P; Micheloud D; Muñoz-Fernández MÁ; Resino S
    J Antimicrob Chemother; 2012 May; 67(5):1238-45. PubMed ID: 22294644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.
    Neukam K; Almeida C; Caruz A; Rivero-Juárez A; Rallón NI; Di Lello FA; Herrero R; Camacho A; Benito JM; Macías J; Rivero A; Soriano V; Pineda JA
    J Antimicrob Chemother; 2013 Apr; 68(4):915-21. PubMed ID: 23243129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.